tbuckley/cabot-search huggingface dataset:
Long noncoding RNAs: emerging regulators of normal and malignant hematopoiesis
Authors: Yi Qiu, Mingjiang Xu, Suming Huang
Journal: Blood (2021)

Genome-wide analyses have revealed that long noncoding RNAs (lncRNAs) are not only passive transcription products, but also major regulators of genome structure and transcription. In particular, lncRNAs exert profound effects on various biological processes, such as chromatin structure, transcription, RNA stability and translation, and protein degradation and localization, that depend on their localization and interacting partners. Recent studies have revealed that thousands of lncRNAs are aberrantly expressed in various cancer types, and some are associated with malignant transformation. Despite extensive efforts, the diverse functions of lncRNAs and molecular mechanisms in which they act remain elusive. Many hematological disorders and malignancies primarily result from genetic alterations that lead to the dysregulation of gene regulatory networks required for cellular proliferation and differentiation. Consequently, a growing list of lncRNAs has been reported to be involved in the modulation of hematopoietic gene expression networks and hematopoietic stem and progenitor cell (HSPC) function. Dysregulation of some of these lncRNAs has been attributed to the pathogenesis of hematological malignancies. In this review, we summarize current advances and knowledge of lncRNAs in gene regulation, focusing on recent progress on the role of lncRNAs in CTCF/cohesin-mediated 3-dimensional genome organization and how such genome folding signals, in turn, regulate transcription, HSPC function, and transformation. This knowledge will provide mechanistic and translational insights into HSPC biology and myeloid malignancy pathophysiology.
Chemo-photothermal immunotherapy for eradication of orthotopic tumors and inhibition of metastasis by intratumoral injection of polydopamine versatile hydrogels
Authors: Bo Zhuang, Ting Chen, Yueqi Huang, Zhimei Xiao, Yiguang Jin
Journal: Acta Pharmaceutica Sinica B (2021)

Cancer remains one of the leading causes of death globally and metastasis always leads to treatment failure. Here, we develop a versatile hydrogel loading photothermal agents, chemotherapeutics, and immune-adjuvants to eradicate orthotopic tumors and inhibit metastasis by combinational therapy. Hydrogel networks were synthesized via the thiol-Michael addition of polydopamine (PDA) with thiolated hyaluronic acid. PDA acted as a cross-linking agent and endowed the hydrogel with excellent photothermal property. Meanwhile, a chemotherapeutic agent, doxorubicin (DOX), was loaded in the hydrogel via π‒π stacking with PDA and an immune-adjuvant, CpG-ODN, was loaded via electrostatic interaction. The release of DOX from the hydrogel was initially slow but accelerated due to near infrared light irradiation. The hydrogels showed remarkably synergistic effect against 4T1 cancer cells and stimulated plenty of cytokines secreting from RAW264.7 cells. Moreover, the hydrogels eradicated orthotopic murine breast cancer xenografts and strongly inhibited metastasis after intratumoral injection and light irradiation. The high anticancer efficiency of this chemo-photothermal immunotherapy resulted from the strong synergistic effect of the versatile hydrogels, including the evoked host immune response. The combinational strategy of chemo-photothermal immunotherapy is promising for highly effective treatment of breast cancer.
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial
Authors: Edmond M. Kwan, Lavinia Spain, Angelyn Anton, Chun L. Gan, Linda Garrett, Deborah Chang, Elizabeth Liow, Caitlin Bennett, Tiantian Zheng, Jianjun Yu, Chao Dai, Pan Du, Shidong Jia, Heidi Fettke, Claire Abou-Seif, Gargi Kothari, Mark Shaw, Phillip Parente, Carmel Pezaro, Ben Tran, Shankar Siva, Arun A. Azad
Journal: European Urology (2021)
Vaccination with a DNA and MVA ‘Prime-Boost’ Regimen Induces Strong CD8+ T-Cell Responses Against the Immunodominant Minor Histocompatibility Antigen, HA-1: Results of a First-in-Man Phase I Clinical Trial
Authors: Charlotte F Inman, Suzy A Eldershaw, Hayden Pearce, Ben E Abbotts, Mirjana Sirovica, Paul Ferguson, Donna L Walsh, Jane Nunnick, Shamyla Siddique, Paul Moss, Ram K Malladi
Journal: Blood (2017)
Effect of the STAMP (Sharing and Talking About My Preferences) Intervention on Completing Multiple Advance Care Planning Activities in Ambulatory Care
Authors: Terri R. Fried, Andrea L. Paiva, Colleen A. Redding, Lynne Iannone, John R. O’Leary, Maria Zenoni, Megan M. Risi, Slawomir Mejnartowicz, Joseph S. Rossi
Journal: Annals of Internal Medicine (2021)

Interventions with the potential for broad reach in ambulatory settings are necessary to achieve a life course approach to advance care planning.To examine the effect of a computer-tailored, behavioral health model-based intervention on the engagement of adults in advance care planning recruited from ambulatory care settings.Cluster randomized controlled trial with participant-level analysis. (ClinicalTrials.gov: NCT03137459).10 pairs of primary and selected specialty care practices matched on patient sociodemographic information.English-speaking adults aged 55 years or older; 454 adults at practices randomly assigned to usual care and 455 at practices randomly assigned to intervention.Brief telephone or web-based assessment generating a mailed, individually tailored feedback report with a stage-matched brochure at baseline, 2 months, and 4 months.The primary outcome was completion of the following 4 advance care planning activities at 6 months: identifying and communicating with a trusted person about views on quality versus quantity of life, assignment of a health care agent, completion of a living will, and ensuring that the documents are in the medical record-assessed by a blinded interviewer. Secondary outcomes were completion of individual advance care planning activities.Participants were 64% women and 76% White. The mean age was 68.3 years (SD, 8.3). The predicted probability of completing all advance care planning activities in usual care sites was 8.2% (95% CI, 4.9% to 11.4%) versus 14.1% (CI, 11.0% to 17.2%) in intervention sites (adjusted risk difference, 5.2 percentage points [CI, 1.6 to 8.8 percentage points]). Prespecified subgroup analysis found no statistically significant interactions between the intervention and age, education, or race.The study was done in a single region and excluded non-English speaking participants. No information was collected about nonparticipants.A brief, easily delivered, tailored print intervention increased participation in advance care planning in ambulatory care settings.National Institute of Nursing Research and National Institute of Aging.
Reply
Authors: Hirofumi Hirao, Takahiro Ito, Jerzy W. Kupiec‐Weglinski, Fady M. Kaldas
Journal: Hepatology (2021)

We thank Bekki et al. for their insightful comments on our published article in Hepatology, in which we demonstrated the impact of donor occult fibrosis on liver transplant (LT) outcomes, including ischemia‐reperfusion injury (IRI) and early allograft dysfunction (EAD). First, we agree that liver biopsies can be easily obtained at time of organ procurement, but liver pathologists are not always available at the donor hospital. Therefore, it may be preferable that the evaluation of graft fibrosis can be substituted by an alternative less invasive, simple, and straightforward method. Given that Sirius red–positive area (SRA), not donor BARD score, was one of the independent predictive factors for EAD in our study, we proposed to analyze SRA in donor liver to predict LT outcomes. Future studies need to address as to how BARD score could reflect SRA accurately and predict LT outcomes in a larger patient cohort. Second, we captured each specimen at 200× magnification to acquire the higher‐resolution images because we sought to analyze "occult fibrosis," which might be difficult to evaluate with hematoxylin and eosin staining, and calculated SRA, whereas some other studies used 40×[1] or 100×[2] magnification. Because of the technological advances and differences in methodology, we are not able to compare the results from the different studies.[3] We recognize that we cannot exclude the possibility that we might overestimate SRA. Hence, the establishment of the standardized method of the evaluation for SRA is warranted. Third, we demonstrated that IRI+ recipients had hepatic macrophages with a higher amount of cytoplasmic disulfide (not all thiol) HMGB1 (high‐mobility group box 1), which provoked macrophages toward a proinflammatory phenotype.[4] However, whether the total amount of hepatic HMGB1 expression correlated with IRI severity was not evaluated in this study. As we have reported,[5] we speculate that the major resource of extracellular HMGB1, as observed in the recipients' liver flush, is damaged hepatocytes. Therefore, we evaluated total intrahepatic HMGB1 as an indicator of hepatocellular damage. We agree that future studies are warranted to further elucidate whether SRA correlates with all thiol and/or disulfide HMGB1 in the postreperfused livers and liver flush. CONFLICT OF INTEREST Nothing to report. AUTHOR CONTRIBUTIONS Hirofumi Hirao, Takahiro Ito, Jerzy W. Kupiec‐Weglinski, and Fady M. Kaldas contributed to concept and design. Hirofumi Hirao and Takahiro Ito contributed to draft of article. Jerzy W. Kupiec‐Weglinski and Fady M. Kaldas contributed to critical review, commentary or revision. All authors have given final approval of the version to be published.
Real‐world evidence of reduced disability costs during the Finnish Allergy Programme 2008–2018
Authors: Juha Jantunen, Paula Kauppi, Miika Linna, Mika Mäkelä, Anna Pelkonen, Tari Haahtela
Journal: Allergy (2021)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Racial and Ethnic Differences in Age at Diabetes Diagnosis—A Call for Action
Authors: Anjali Gopalan, Anand R. Habib, Richard W. Grant
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia
Authors: Deena Iskander, Guanlin Wang, Elisabeth F. Heuston, Chrysi Christodoulidou, Bethan Psaila, Kanagaraju Ponnusamy, Hongwei Ren, Zeinab Mokhtari, Mark Robinson, Aristeidis Chaidos, Pritesh Trivedi, Nikolaos Trasanidis, Alexia Katsarou, Richard Szydlo, Carmen G. Palii, Mehmood H. Zaidi, Qais Al-Oqaily, Valentina S. Caputo, Anindita Roy, Yvonne Harrington, Leena Karnik, Kikkeri Naresh, Adam J. Mead, Supat Thongjuea, Marjorie Brand, Josu de la Fuente, David M. Bodine, Irene Roberts, Anastasios Karadimitris
Journal: Science Translational Medicine (2021)

Genotype-phenotype correlations are revealed by bone marrow single-cell RNA sequencing in Diamond-Blackfan anemia.
FNDC4 and FNDC5 reduce SARS-CoV-2 entry points and spike glycoprotein S1-induced pyroptosis, apoptosis, and necroptosis in human adipocytes
Authors: Gema Frühbeck, Victoria Catalán, Víctor Valentí, Rafael Moncada, Javier Gómez-Ambrosi, Sara Becerril, Camilo Silva, Piero Portincasa, Javier Escalada, Amaia Rodríguez
Journal: Cellular and Molecular Immunology (2021)
A reservoir of stem-like CD8 <sup>+</sup> T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response
Authors: Kelli A. Connolly, Manik Kuchroo, Aarthi Venkat, Achia Khatun, Jiawei Wang, Ivana William, Noah I. Hornick, Brittany L. Fitzgerald, Martina Damo, Moujtaba Y. Kasmani, Can Cui, Eric Fagerberg, Isabel Monroy, Amanda Hutchins, Julie F. Cheung, Gena G. Foster, Dylan L. Mariuzza, Mursal Nader, Hongyu Zhao, Weiguo Cui, Smita Krishnaswamy, Nikhil S. Joshi
Journal: Science Immunology (2021)

Tumor-specific CD8 + T cells in stable tumor-draining lymph node reservoir are clonally and developmentally related to those in tumors.
Ensuring Access to Albuterol in Schools: From Policy to Implementation. An Official ATS/AANMA/ALA/NASN Policy Statement
Authors: Anna Volerman, Ashley A. Lowe, Andrea A. Pappalardo, Charmayne M. C. Anderson, Kathryn V. Blake, Tyra Bryant-Stephens, Thomas Carr, Heather Carter, Lisa Cicutto, Joe K. Gerald, Tina Miller, Nuala S. Moore, Hanna Phan, S. Christy Sadreameli, Andrea Tanner, Tonya A. Winders, Lynn B. Gerald
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

Section:ChooseTop of pageAbstract <<IntroductionMethodsSteps to Pass Stock Albut...Components for Implementa...ConclusionsReferences
Electronic Health Record Interoperability—Why Electronically Discontinued Medications Are Still Dispensed
Authors: Saira Shervani, William Madden, Lauren J. Gleason
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia
Authors: Bettina Winzeler, Clara O. Sailer, David Coynel, Davide Zanchi, Deborah R. Vogt, Sandrine A. Urwyler, Julie Refardt, Mirjam Christ-Crain
Journal: Journal of Clinical Investigation (2021)

BackgroundPrimary polydipsia, characterized by excessive fluid intake, carries the risk of water intoxication and hyponatremia, but treatment options are scarce. Glucagon-like peptide 1 (GLP-1) reduces appetite and food intake. In experimental models, GLP-1 has also been shown to play a role in thirst and drinking behavior. The aim of this trial was to investigate whether GLP-1 receptor agonists reduce fluid intake in patients with primary polydipsia.MethodsIn this randomized, double-blind, placebo-controlled, 3-week crossover trial, 34 patients with primary polydipsia received weekly dulaglutide (1.5 mg, Trulicity) in one treatment segment and placebo (0.9% sodium chloride) in the other. During the last treatment week, patients attended an 8-hour evaluation visit with free access to water. The primary endpoint was total fluid intake during the evaluation visits. Treatment effects were estimated using linear mixed-effects models. In a subset of 15 patients and an additional 15 matched controls, thirst perception and neuronal activity in response to beverage pictures were assessed by functional MRI.RESULTsPatients on dulaglutide reduced their fluid intake by 490 mL (95% CI: -780, -199; P = 0.002), from 2950 mL (95% CI: 2435, 3465) on placebo to 2460 mL (95% CI: 1946, 2475) on dulaglutide (model estimates), corresponding to a relative reduction of 17%. Twenty-four-hour urinary output was reduced by -943 mL (95% CI: -1473, -413; P = 0.001). Thirst perception in response to beverage pictures was higher for patients with primary polydipsia than for controls, and lower for patients on dulaglutide versus placebo, but functional activity was similar among groups and treatments.CONCLUSIONSGLP-1 receptor agonists reduce fluid intake and thirst perception in patients with primary polydipsia and could therefore be a treatment option for these patients.Trial registrationClinicaltrials.gov NCT02770885.FundingSwiss National Science Foundation (grant 32473B_162608); University Hospital and University of Basel; Young Talents in Clinical Research grant from the Swiss Academy of Medical Sciences and the Gottfried & Julia Bangerter-Rhyner Foundation; Top-up Grant from the PhD Programme in Health Sciences, University of Basel.
Abstract 12206: Fully Automated 3D Deep-Learning Analysis of Coronary CT Angiography : Prediction of Fractional Flow Reserve
Authors: Yuko O Kawaguchi, Shinichiro Fujimoto, Kanako K Kumamaru, Yujiro Otsuka, Etsuro Kato, Chihiro Aoshima, Kazuhisa Takamura, Makoto Hiki, Shigeki Aoki, Hiroyuki Daida
Journal: Circulation (2018)

Introduction: Recently, deep-learning such as convolution neural network has been conducted in image diagnostic field as “artificial intelligence” variously. However, its reports using 3D image dat...
Abstract 12694: Sex Based Differences in Outcomes Among Patients Undergoing Catheter Directed Therapy for Pulmonary Embolism
Authors: Srilekha Sridhara, Rishita Shah, Abhishek Sawant, Edward Distler, Nidhi Kanwar, Ashish Pershad, Mehul Shah
Journal: Circulation (2019)

Background: Catheter directed therapy (CDT) has been shown to be safe and effective management strategy for sub-massive pulmonary embolism (PE). However, gender-based outcomes are lacking in curren...
Policies to Promote Shared Responsibility for Safer Electronic Health Records
Authors: Dean F. Sittig, Hardeep Singh
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Why do clinicians treat, or not treat, a patient for sepsis? Using the theoretical domains framework to elicit barriers and enablers to performing the Sepsis Six in UK hospitals
Authors: Dr Guy Hooper, Dr Neil Roberts, Dr Fabiana Lorencatto, Dr Adam Pollard, Dr Michael Spivey, Dr Wendell Storr, Dr Deborah Webster, Mr Alan Eccles, Mr George Ramsay, Dr Jan Jansen, Dr Ruth Thomas, Dr Helen Bounds, Dr Michael Eddie, Dr Stephen Knight, Dr Robert Pearson, Dr James Chean Khun Ng, Ms Theresa Weldring, Ms Sandra Courtiour, Ms Laura Smith, Ms Nicola DeVeaux, Dr Biju Cherian, Toby Flack, Stephen Rogen, Nadia Mekki, Hope Ward, Sian Edwards, Nigel Booth, Heather Clarke, Samantha Rowe, Kate Adams, Donna Gotts
Journal: Journal of Infection (2021)
Antegrade metal stent deployment under endoscopic ultrasound guidance using a novel uncovered metal stent with a fine-gauge stent delivery system
Authors: Akira Miyano, Takeshi Ogura, Saori Ueno, Nobu Nishioka, Kazuhide Higuchi
Journal: Endoscopy (2021)

Endoscopic ultrasound-guided antegrade stent deployment (EUS-AS) has recently been performed for patients with inaccessible papilla, for example due to malignant duodenal obstruction or surgically altered anatomy [1] [2] [3]. During EUS-AS, use of a fine-gauge delivery system may prevent bile leakage because tract dilation may not be needed [4]. Additionally, to prevent stent misplacement or dislocation, a laser-cut-type uncovered self-expandable metal stent (UCSEMS) may be favorable compared with a fully covered metal stent (FCSEMS), although stent patency is shorter. Furthermore, cell width is high, so stent patency may be insufficient. Recently, a novel laser-cut-type UCSEMS (YABUSAME; Kaneka, Tokyo, Japan) has become available. Cell width is smaller than in the conventional laser-cut-type UCSEMS in the part where bending force is applied ([Fig. 1]). In addition, the stent delivery system is only 5.4 Fr ([Fig. 2]). Transluminal stent insertion can thus be performed without additional tract dilation. We describe herein technical tips for EUS-AS using this novel stent.
High proportion strontium-doped micro-arc oxidation coatings enhance early osseointegration of titanium in osteoporosis by anti-oxidative stress pathway
Authors: Xinkun Shen, Kai Fang, Kendrick Hii Ru Yie, Zixin Zhou, Yiding Shen, Shuyi Wu, Yue Zhu, Zhennan Deng, Pingping Ma, Jianfeng Ma, Jinsong Liu
Journal: Bioactive Materials (2021)

The excessive accumulation of reactive oxygen species (ROS) under osteoporosis precipitates a microenvironment with high levels of oxidative stress (OS). This could significantly interfere with the bioactivity of conventional titanium implants, impeding their early osseointegration with bone. We have prepared a series of strontium (Sr)-doped titanium implants via micro-arc oxidation (MAO) to verify their efficacy and differences in osteoinduction capabilities under normal and osteoporotic (high OS levels) conditions. Apart from the chemical composition, all groups exhibited similar physicochemical properties (morphology, roughness, crystal structure, and wettability). Among the groups, the low Sr group (Sr25%) was more conducive to osteogenesis under normal conditions. In contrast, by increasing the catalase (CAT)/superoxide dismutase (SOD) activity and decreasing ROS levels, the high Sr-doped samples (Sr75% and Sr100%) were superior to Sr25% in inducing osteogenic differentiation of MC3T3-E1 cells and the M2 phenotype polarization of RAW264.7 cells, thus enhancing early osseointegration. Furthermore, the results of both in vitro cell co-culture and in vivo studies also showed that the high Sr-doped samples (especially Sr100%) had positive effects on osteoimmunomodulation under the OS microenvironment. Ultimately, the collated findings indicated that the high proportion Sr-doped MAO coatings were more favorable for osteoporosis patients in implant restorations.